Kseniya Simpson, PhD


Kseniya is a Principal at Hatteras and focuses on investing in innovative biotech companies. Kseniya currently serves as a board observer for Ten63 Therapeutics, Aer Therapeutics, Trefoil Therapeutics, and Code Bio. She was previously a board observer for Vigil Neuroscience (NASDAQ: VIGL).

Prior to Hatteras, Kseniya was with Triangle Insights Group, where she worked as a Strategy Consultant, advising biotech and pharma companies on a wide variety of topics including company and asset diligence, pipeline strategy, clinical development, and commercial preparedness. Kseniya is a scientist by training and has conducted research in the areas of RNA therapeutics, nucleic acid delivery, lipid monolayers, and tissue engineering. She has also worked at Yale Ventures and served as a teaching fellow and lecturer at Yale.

Kseniya earned a Ph.D. in Cellular and Molecular Physiology from Yale University where she worked on siRNA therapeutics under the mentorship of W. Mark Saltzman, Ph.D. and received the Ruth L. Kirschstein National Research Service Award. She holds B.S. degrees in Chemistry and Biological Chemistry from the University of Chicago.